- Home
- MCHX vs MCRB Comparison
MCHX vs MCRB Comparison
Compare MCHX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- MCRB
- Stock Information
- Founded
- MCHX 2003
- MCRB 2010
- Country
- MCHX United States
- MCRB United States
- Employees
- MCHX N/A
- MCRB N/A
- Industry
- MCHX Business Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- MCHX Consumer Discretionary
- MCRB Health Care
- Exchange
- MCHX Nasdaq
- MCRB Nasdaq
- Market Cap
- MCHX 84.3M
- MCRB 84.0M
- IPO Year
- MCHX 2004
- MCRB 2015
- Fundamental
- Price
- MCHX $1.45
- MCRB $7.37
- Analyst Decision
- MCHX
- MCRB Hold
- Analyst Count
- MCHX 0
- MCRB 5
- Target Price
- MCHX N/A
- MCRB $73.67
- AVG Volume (30 Days)
- MCHX 18.2K
- MCRB 151.3K
- Earning Date
- MCHX 05-13-2025
- MCRB 05-07-2025
- Dividend Yield
- MCHX N/A
- MCRB N/A
- EPS Growth
- MCHX N/A
- MCRB N/A
- EPS
- MCHX N/A
- MCRB 0.03
- Revenue
- MCHX $48,122,000.00
- MCRB N/A
- Revenue This Year
- MCHX $6.83
- MCRB N/A
- Revenue Next Year
- MCHX N/A
- MCRB N/A
- P/E Ratio
- MCHX N/A
- MCRB $223.71
- Revenue Growth
- MCHX N/A
- MCRB N/A
- 52 Week Low
- MCHX $1.23
- MCRB $7.18
- 52 Week High
- MCHX $2.40
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- MCHX 47.74
- MCRB 36.88
- Support Level
- MCHX $1.36
- MCRB $6.64
- Resistance Level
- MCHX $1.50
- MCRB $8.09
- Average True Range (ATR)
- MCHX 0.11
- MCRB 0.85
- MACD
- MCHX 0.01
- MCRB -0.02
- Stochastic Oscillator
- MCHX 59.38
- MCRB 20.19
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.